BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of January 14, 2025, BCTX stock price declined to $0.39 with 387,696 million shares trading.

BCTX has a beta of 1.51, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.02 to the broad based SPY ETF.

BCTX has a market cap of $17.24 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCTX traded as high as $12.09 and as low as $.38.

BCTX has underperformed the market in the last year with a price return of -91.1% while the SPY ETF gained +23.6%. BCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -56.4% and -31.0%, respectively, while the SPY returned 0.0% and -0.7%, respectively.

BCTX support price is $.37 and resistance is $.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.